Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Burgin Jonathan

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/1/2020

3. Issuer Name and Ticker or Trading Symbol

Anchiano Therapeutics Ltd. [ANCN]

(Last) (First) (Middle)

C/O ANCHIANO THERAPEUTICS LTD., 5 KIRYAT HAMADA ST., P.O. BOX 45032

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
See Remarks /

(Street)

JERUSALEM, L3 9777401

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee stock options	⁽¹⁾	9/26/2021	Ordinary Shares	3533	$72.01 ⁽²⁾	D
Employee stock options	⁽³⁾	5/10/2024	Ordinary Shares	4504	$6.79 ⁽⁴⁾	D
Employee stock options	⁽⁵⁾	4/28/2025	Ordinary Shares	6000	$3.13 ⁽⁶⁾	D
Employee stock options	⁽⁷⁾	9/9/2027	Ordinary Shares	100000	$2.60 ⁽⁸⁾	D
Employee stock options	⁽⁹⁾	7/2/2029	Ordinary Shares	226000	$1.03	D

Explanation of Responses:
(1)	1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on June 1, 2011.
(2)	The exercise price was converted from New Israeli Shekel ("NIS") 246.27 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.
(3)	1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on March 2, 2014.
(4)	The exercise price was converted from NIS 23.44 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.
(5)	1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on February 22, 2015.
(6)	The exercise price was converted from NIS 12.10 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.
(7)	1/4 of the options vest one year following the vesting commencement date of September 10, 2017, and 1/16 at the end of each calendar quarter thereafter, until fully vested.
(8)	The exercise price was converted from NIS 9.10 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.
(9)	1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on May 21, 2019.

Remarks:
Chief Financial and Operating Officer

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Burgin Jonathan C/O ANCHIANO THERAPEUTICS LTD. 5 KIRYAT HAMADA ST., P.O. BOX 45032 JERUSALEM, L3 9777401			See Remarks